The effectiveness of COVID-19 vaccines to prevent long COVID symptoms: staggered cohort study of data from the UK, Spain, and Estonia
- PMID: 38219763
- DOI: 10.1016/S2213-2600(23)00414-9
The effectiveness of COVID-19 vaccines to prevent long COVID symptoms: staggered cohort study of data from the UK, Spain, and Estonia
Abstract
Background: Although vaccines have proved effective to prevent severe COVID-19, their effect on preventing long-term symptoms is not yet fully understood. We aimed to evaluate the overall effect of vaccination to prevent long COVID symptoms and assess comparative effectiveness of the most used vaccines (ChAdOx1 and BNT162b2).
Methods: We conducted a staggered cohort study using primary care records from the UK (Clinical Practice Research Datalink [CPRD] GOLD and AURUM), Catalonia, Spain (Information System for Research in Primary Care [SIDIAP]), and national health insurance claims from Estonia (CORIVA database). All adults who were registered for at least 180 days as of Jan 4, 2021 (the UK), Feb 20, 2021 (Spain), and Jan 28, 2021 (Estonia) comprised the source population. Vaccination status was used as a time-varying exposure, staggered by vaccine rollout period. Vaccinated people were further classified by vaccine brand according to their first dose received. The primary outcome definition of long COVID was defined as having at least one of 25 WHO-listed symptoms between 90 and 365 days after the date of a PCR-positive test or clinical diagnosis of COVID-19, with no history of that symptom 180 days before SARS-Cov-2 infection. Propensity score overlap weighting was applied separately for each cohort to minimise confounding. Sub-distribution hazard ratios (sHRs) were calculated to estimate vaccine effectiveness against long COVID, and empirically calibrated using negative control outcomes. Random effects meta-analyses across staggered cohorts were conducted to pool overall effect estimates.
Findings: A total of 1 618 395 (CPRD GOLD), 5 729 800 (CPRD AURUM), 2 744 821 (SIDIAP), and 77 603 (CORIVA) vaccinated people and 1 640 371 (CPRD GOLD), 5 860 564 (CPRD AURUM), 2 588 518 (SIDIAP), and 302 267 (CORIVA) unvaccinated people were included. Compared with unvaccinated people, overall HRs for long COVID symptoms in people vaccinated with a first dose of any COVID-19 vaccine were 0·54 (95% CI 0·44-0·67) in CPRD GOLD, 0·48 (0·34-0·68) in CPRD AURUM, 0·71 (0·55-0·91) in SIDIAP, and 0·59 (0·40-0·87) in CORIVA. A slightly stronger preventative effect was seen for the first dose of BNT162b2 than for ChAdOx1 (sHR 0·85 [0·60-1·20] in CPRD GOLD and 0·84 [0·74-0·94] in CPRD AURUM).
Interpretation: Vaccination against COVID-19 consistently reduced the risk of long COVID symptoms, which highlights the importance of vaccination to prevent persistent COVID-19 symptoms, particularly in adults.
Funding: National Institute for Health and Care Research.
Copyright © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of interests DP-A's department has received grants from Amgen, Chiesi-Taylor, Lilly, Janssen, Novartis, UCB Biopharma, the European Medicines Agency, and the Innovative Medicines Initiative. DP-A's research group has received consultancy fees from Astra Zeneca and UCB Biopharma. DP-A's department has organised training programmes funded or supported by Amgen, Astellas, Janssen, Synapse Management Partners, and UCB Biopharma. RK's research group has received consultancy fees from AstraZeneca and the Estonian Ministry of Social Affairs through RITA CORIVA and RITA MAITT (Machine learning and AI powered public services) projects. AU reports funding from the European Regional Development Fund (RITA 1/02–120) for her institution (Department of Family Medicine and Public Health, University of Tartu). HMEN reports support from the European Health Data and Evidence Network project grant, Innovative Medicines Initiative 2 Joint Undertaking (grant agreement 806968) for harmonisation of the Norwegian registry data into the Observational Medical Outcomes Partnership (OMOP) common data model (CDM). TD-S reports funding from the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement 806968) for the institute to map the SIDIAP data to the OMOP CDM. This initiative received support from the EU Horizon 2020 research and innovation programme and European Federation of Pharmaceutical Industries and Associations. All other authors declare no competing interests.
Similar articles
-
Observational methods for COVID-19 vaccine effectiveness research: an empirical evaluation and target trial emulation.Int J Epidemiol. 2024 Feb 1;53(1):dyad138. doi: 10.1093/ije/dyad138. Int J Epidemiol. 2024. PMID: 37833846 Free PMC article. Clinical Trial.
-
Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose: OpenSAFELY cohort study using linked electronic health records.BMJ. 2022 Jul 20;378:e071249. doi: 10.1136/bmj-2022-071249. BMJ. 2022. PMID: 35858698 Free PMC article.
-
Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study.Lancet Infect Dis. 2022 Jan;22(1):43-55. doi: 10.1016/S1473-3099(21)00460-6. Epub 2021 Sep 1. Lancet Infect Dis. 2022. PMID: 34480857 Free PMC article.
-
Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study.Lancet Infect Dis. 2021 Nov;21(11):1529-1538. doi: 10.1016/S1473-3099(21)00289-9. Epub 2021 Jun 23. Lancet Infect Dis. 2021. PMID: 34174193 Free PMC article.
-
COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study.Lancet. 2021 May 8;397(10286):1725-1735. doi: 10.1016/S0140-6736(21)00790-X. Epub 2021 Apr 23. Lancet. 2021. PMID: 33901423 Free PMC article.
Cited by
-
Evaluating qigong as integrative support for COVID-19 and Long-COVID-19 rehabilitation: a systematic review.Front Psychol. 2024 May 14;15:1403130. doi: 10.3389/fpsyg.2024.1403130. eCollection 2024. Front Psychol. 2024. PMID: 38807958 Free PMC article.
-
Clinical coding of long COVID in primary care 2020-2023 in a cohort of 19 million adults: an OpenSAFELY analysis.EClinicalMedicine. 2024 May 17;72:102638. doi: 10.1016/j.eclinm.2024.102638. eCollection 2024 Jun. EClinicalMedicine. 2024. PMID: 38800803 Free PMC article.
-
The Potential Role of Viral Persistence in the Post-Acute Sequelae of SARS-CoV-2 Infection (PASC).Pathogens. 2024 May 8;13(5):388. doi: 10.3390/pathogens13050388. Pathogens. 2024. PMID: 38787240 Free PMC article. Review.
-
Post-COVID-19 cognitive symptoms in patients assisted by a teleassistance service: a retrospective cohort study.Front Public Health. 2024 Apr 16;12:1282067. doi: 10.3389/fpubh.2024.1282067. eCollection 2024. Front Public Health. 2024. PMID: 38689777 Free PMC article.
-
The role of COVID-19 vaccines in preventing post-COVID-19 thromboembolic and cardiovascular complications.Heart. 2024 Apr 15;110(9):635-643. doi: 10.1136/heartjnl-2023-323483. Heart. 2024. PMID: 38471729 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous